Seroatlas · Human Serome Atlas

SLC19A3

Thiamine transporter 2

Also known as: S19A3_HUMAN, THTR2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9BZV2
Gene
SLC19A3
Ensembl
ENSG00000135917
Chromosome
2
Canonical length
496 aa
Protein class
Disease related genes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted membrane proteins, Transporters
Subcellular location
Nucleoplasm,Plasma membrane,Cytosol

OverviewNCBI Gene

This gene encodes a ubiquitously expressed transmembrane thiamine transporter that lacks folate transport activity. Mutations in this gene cause biotin-responsive basal ganglia disease (BBGD); a recessive disorder manifested in childhood that progresses to chronic encephalopathy, dystonia, quadriparesis, and death if untreated. Patients with BBGD have bilateral necrosis in the head of the caudate nucleus and in the putamen. Administration of high doses of biotin in the early progression of the disorder eliminates pathological symptoms while delayed treatment results in residual paraparesis, mild cognitive disability, or dystonia. Administration of thiamine is ineffective in the treatment of this disorder. Experiments have failed to show that this protein can transport biotin. Mutations in this gene also cause a Wernicke's-like encephalopathy.[provided by RefSeq, Jan 2010]

Canonical amino-acid sequenceUniProt

496 residues, UniProt reviewed canonical sequence.

>Q9BZV2|SLC19A3
     1  MDCYRTSLSS SWIYPTVILC LFGFFSMMRP SEPFLIPYLS GPDKNLTSAE ITNEIFPVWT
    61  YSYLVLLLPV FVLTDYVRYK PVIILQGISF IITWLLLLFG QGVKTMQVVE FFYGMVTAAE
   121  VAYYAYIYSV VSPEHYQRVS GYCRSVTLAA YTAGSVLAQL LVSLANMSYF YLNVISLASV
   181  SVAFLFSLFL PMPKKSMFFH AKPSREIKKS SSVNPVLEET HEGEAPGCEE QKPTSEILST
   241  SGKLNKGQLN SLKPSNVTVD VFVQWFQDLK ECYSSKRLFY WSLWWAFATA GFNQVLNYVQ
   301  ILWDYKAPSQ DSSIYNGAVE AIATFGGAVA AFAVGYVKVN WDLLGELALV VFSVVNAGSL
   361  FLMHYTANIW ACYAGYLIFK SSYMLLITIA VFQIAVNLNV ERYALVFGIN TFIALVIQTI
   421  MTVIVVDQRG LNLPVSIQFL VYGSYFAVIA GIFLMRSMYI TYSTKSQKDV QSPAPSENPD
   481  VSHPEEESNI IMSTKL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLC19A3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
12
Mean surface accessibility (rSASA)
0.32
Highest tissue expression
44 nTPM

Expression across tissuesHPA

Tissue

  • adipose tissue: 44 nTPM
  • placenta: 23 nTPM
  • breast: 19 nTPM
  • liver: 13 nTPM
  • duodenum: 8.5 nTPM
  • gallbladder: 5.4 nTPM

Single-cell type

  • adipocytes: 672 nCPM
  • syncytiotrophoblasts: 311 nCPM
  • distal convoluted tubule cells: 197 nCPM
  • cytotrophoblasts: 137 nCPM
  • migrating cytotrophoblasts: 72 nCPM
  • renal connecting tubule cells: 34 nCPM

Immune cell

  • basophil: 6.9 nTPM
  • neutrophil: 3.2 nTPM
  • NK-cell: 2.2 nTPM
  • naive B-cell: 1.2 nTPM
  • eosinophil: 0.9 nTPM
  • plasmacytoid DC: 0.9 nTPM

Brain region

  • thalamus: 19 nTPM
  • pons: 18 nTPM
  • medulla oblongata: 18 nTPM
  • amygdala: 17 nTPM
  • spinal cord: 17 nTPM
  • cerebellum: 17 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SLC19A3.

Disease | AllUniProt

Conditions SLC19A3 is implicated in, by any mechanism.

Disease | GeneticClinVar

77 pathogenic / likely-pathogenic of 714 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.59
gnomAD pLI
0.1
gnomAD missense Z
-0.37
DepMap mean gene effect
-0.11
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLC19A3 as an antibody target. Whether an autoantibody or antibody against SLC19A3 could matter depends on whether native SLC19A3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLC19A3 is annotated at the cell surface, where native SLC19A3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLC19A3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SLC19A3. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...